Antifungal susceptibility, clinical findings, and biofilm resistance of Fusarium species causing keratitis: a challenge for disease control

Abstract

Fusarium keratitis (FK) is an important clinical condition that can lead to blindness and eye loss, and is most commonly caused by the Fusarium solani species complex (FSSC). This study evaluated the susceptibility of planktonic cells and biofilms of FSSC (n = 7) and non-FSSC (n = 7) isolates obtained from patients with keratitis from a semi-arid tropical region to amphotericin B (AMB), natamycin (NAT), voriconazole (VRZ), efinaconazole (EFZ), and luliconazole (LCZ). Analysis of clinical data showed that trauma was the most common risk factor for FK patients. Disease onset was longer in non-FSSC group (3-30 days) than in the FSSC group (3-7 days). FSSC strains were less susceptible to AMB and VRZ than non-FSSC strains (p < 0.05). Susceptibility to NAT, LCZ and EFZ was similar between isolates of FSSC and non-FSSC groups. Overall, patients infected with non-FSSC showed a better response to antifungal treatment. Corneal transplantation was more common in patients infected with FSSC (3/7) than in those infected with non-FSSC (1/7). Mature biofilms showed a poor response to antifungal treatment. Patients infected with Fusarium strains capable of forming antifungal tolerant biofilms had more complex therapeutic management, requiring two antifungals and/or corneal transplantation (p < 0.05). This study highlights the importance of mycological diagnosis and the antifungal susceptibility testing in the clinical management of FK. The ability of Fusarium to form antifungal tolerant biofilms poses a challenge to clinicians and urges the development of new antibiofilm therapeutics.

Keywords: Efinaconazole; Fungal keratitis; Luliconazole Fusarium solani species complex.